New combo therapy aims to keep recurrent prostate cancer at bay
NCT ID NCT06096870
Summary
This study is testing whether adding an immunotherapy injection (PDS01ADC) to a standard prostate cancer pill (enzalutamide) works better than the pill alone for men whose cancer has returned after initial treatment. The goal is to control the cancer and delay its progression for a longer time without using testosterone-lowering therapy, which can have significant side effects. About 65 men with recurrent prostate cancer visible on a special PET scan will receive either the pill alone or the pill plus the monthly injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.